Question

Is denosumab chemotherapy?

Answer 1

No the denosumab drug is not a chemotherapy drug.

Denosumab which is also known as Xgeva is not a chemotherapy drug.

Instead it is a targeted treatment, called a monoclonal antibody and is classified as a bone-modifying agent.

Although it is not a chemotherapy drug it is often given with chemotherapy medicines.

Denosumab injection (Xgeva) is used Denosumab injection is in a class of medications called RANK ligand inhibitors.

It works to prevent bone loss by blocking a certain receptor in the body to decrease bone breakdown.

It works to treat GCTB by blocking a certain receptor in the tumor cells which slows the tumor growth.

Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.

Denosumab is contraindicated in people with low blood calcium levels.

Denosumab injection (Xgeva) is used Denosumab injection is in a class of medications called RANK ligand inhibitors.

It works to prevent bone loss by blocking a certain receptor in the body to decrease bone breakdown.

It works to treat GCTB by blocking a certain receptor in the tumor cells which slows the tumor growth.

In clinical trials of women with osteoporosis and low bone mineral density, denosumab has been well tolerated, with overall rates of adverse events and serious adverse events in women treated with denosumab similar to those receiving placebo.

People with rare hereditary problems of fructose intolerance should not use denosumab.

This medicinal product contains less than 1 mmol sodium (23 mg) per 60 mg i.e. essentially 'sodium-free'.

Answer 2

Denosumab injections are used to treat osteoporosis which is caused by corticosteroid medications in men and women who will be taking corticosteroid medications for at least 6 months and have an increased risk for fractures or who cannot take or did not respond to other medication treatments for osteoporosis.

Denosumab is also known by its brand names, Xgeva and Prolia.

It helps to prevent fractures and other cancer related bone problems in adults with cancer that has spread to the bones.

Prolia can reduce the risk of spinal fractures in men who have weakened bones due to hormone therapy for prostate cancer.

Antiresorptive drugs (e.g. bisphosphonates, oestrogen, denosumab) reduce bone turnover by distinct mechanisms.

Denosumab, a recently approved therapy, is a fully human monoclonal antibody that binds the cytokine RANKL (receptor activator of NFκB ligand), an essential factor initiating bone turnover.